Total Cost
Free shipping on all orders
To place an order please call (833) 812 - 0565

brand durezol 0.05% eye drops

In stock Manufacturer ALCON/NOVARTIS 00065924007
$195.00 / 5 Milliliters Drop Btl

Select Quantity

Prescription is required


Postoperative Ocular Inflammation and Pain

Difluprednate ophthalmic emulsion is used for the treatment of inflammation and pain associated with ocular surgery.

Efficacy of difluprednate has been evaluated in 2 randomized, double-blind, placebo-controlled studies in patients who had undergone cataract surgery. In these studies, patients with an anterior chamber cell grade of 2 or higher (a cell count of 11 or higher) after cataract surgery were randomized to receive either difluprednate 0.05% ophthalmic emulsion (1 drop 2 or 4 times daily) or vehicle for 14 days, beginning the day after surgery. At 8 days postoperatively, reduction of ocular inflammation (anterior chamber cell clearing) or absence of ocular pain was achieved in 22 or 58%, respectively, of patients receiving difluprednate (1 drop 4 times daily) compared with 7 or 27%, respectively, of those receiving vehicle. At 15 days postoperatively, anterior chamber cell clearing or absence of ocular pain was achieved in 41 or 63%, respectively, of patients receiving difluprednate (1 drop 4 times daily) compared with 11 or 35%, respectively, of those receiving vehicle.

Dosage and Administration


Difluprednate is applied topically in the conjunctival sac of the affected eye(s) as an ophthalmic emulsion. Care should be taken to avoid contamination of the emulsion container.

Patients should refrain from wearing contact lenses during therapy with difluprednate ophthalmic emulsion unless specifically directed by a clinician.

Difluprednate ophthalmic emulsion may be used in conjunction with other topical ophthalmic drugs such as β-adrenergic blocking agents, carbonic anhydrase inhibitors, α-agonists, cycloplegics, and mydriatics. If the patient is receiving more than one topical ophthalmic drug, the drugs should be administered 10 minutes apart from difluprednate administration.


The recommended initial adult dosage of difluprednate for the treatment of postoperative inflammation and pain in patients who have undergone ocular surgery is 1 drop of a 0.05% emulsion in the affected eye(s) 4 times daily, beginning 24 hours after surgery and continuing throughout the first 2 weeks of the postoperative period. After 2 weeks of therapy, dosage should be reduced to 1 drop twice daily for 1 week and then gradually tapered according to response.

Special Populations

No special population recommendations at this time.



Most active viral diseases of the cornea and conjunctiva (including epithelial herpes simplex keratitis [dendritic keratitis], vaccinia, and varicella [chickenpox]); mycobacterial infection of the eye; and fungal diseases of ocular structures.

Known hypersensitivity to difluprednate, other corticosteroids, or any ingredient in the formulation.


Ocular Effects

Glaucoma (with optic nerve damage and defects in visual acuity and fields of vision) may occur with long-term use of corticosteroids. Corticosteroids should be used with caution in patients with glaucoma. Intraocular pressure should be monitored if difluprednate is used for 10 days or longer.

Posterior subcapsular cataract formation also may occur with use of corticosteroids.

Wound Healing Complications

Use of corticosteroids after cataract surgery may delay healing and increase the incidence of bleb formation. In conditions causing thinning of the cornea or sclera, perforations have been reported following use of topical corticosteroids.

Careful monitoring, including slit-lamp biomicroscopy and fluorescein staining when appropriate, is necessary in patients requiring difluprednate therapy for longer than 28 days.

Increased Susceptibility to Infections

Prolonged use of corticosteroids may increase the risk of secondary ocular infections. In acute purulent conditions, corticosteroids may mask infection or exacerbate existing infection. If signs and symptoms fail to improve after 2 days, the patient should be reevaluated.

Use of ophthalmic corticosteroids may prolong and exacerbate ocular viral infections (e.g., herpes simplex). Difluprednate should be used with extreme caution in patients with a history of herpes simplex virus infection.

Fungal infections of the cornea are particularly prone to develop following long-term use of ophthalmic corticosteroids. The possibility of fungal infection must be considered in patients receiving corticosteroids who present with persistent corneal ulceration. Fungal culture should be obtained when appropriate.

Specific Populations


Category C.


Systemically administered corticosteroids distribute into milk and may suppress growth, interfere with endogenous corticosteroid production, or cause other adverse effects. It is not known whether topical ophthalmic administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in milk; caution if used in nursing women.

Pediatric Use

Safety and efficacy not established in pediatric patients.

Geriatric Use

No substantial differences in safety and efficacy relative to younger adults.

Common Adverse Effects

Adverse ocular effects reported in 5-15% of patients receiving difluprednate include corneal edema, ciliary and conjunctival hyperemia, eye pain, photophobia, posterior capsule opacification, anterior chamber cells, anterior chamber flare, conjunctival edema, and blepharitis. Adverse ocular effects reported in 1-5% of patients include reduced visual acuity, punctate keratitis, eye inflammation, and iritis.

Drug Interactions

No formal drug interaction studies have been performed to date.

Write Your Own Review

Your meds on autopilot. Forever.